Revenue
No reported data
MapLight Therapeutics, Inc. (MPLT)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Research & development | $138.3M | $68.5M |
| Operating expenses | $169.1M | $82.9M |
| Operating income | −$169.1M | −$82.9M |
| Net income | −$161.2M | −$77.6M |
| Basic EPSper diluted share | -$18.56 | -$105.38 |
| Diluted EPSper diluted share | -$18.56 | -$105.38 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 · 10b5-1 | Kroeger Christopher A.Chief Executive Officer | SellVoting Common Stock | 198 | $28.15 | $5.6K | 1.39M |
| May 18, 2026Form 4 · 10b5-1 | Kroeger Christopher A.Chief Executive Officer | SellVoting Common Stock | 118.0K | $27.19 | $3.21M | 1.39M |
| May 11, 2026Form 4 · 10b5-1 | Hanson KristopherGeneral Counsel | SellVoting Common Stock | 5.8K | $30.56 | $177.5K | 162.3K |
| May 11, 2026Form 4 · 10b5-1 | Hanson KristopherGeneral Counsel | SellVoting Common Stock | 7.0K | $30.04 | $209.6K | 168.1K |
| May 11, 2026Form 4 · 10b5-1 | Hanson KristopherGeneral Counsel | SellVoting Common Stock | 846 | $28.70 | $24.3K | 175.1K |